Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in North Carolina

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Inquiry

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This broad heritage encompasses the dissemination of knowledge about chronic diseases, medication management, and the importance of informed patient-provider communication. Within this framework, discussions of diabetes management and weight loss therapies have been standard, with an emphasis on lifestyle modification and pharmacological interventions. As the landscape of pharmaceutical treatments evolves, a specific area of concern has emerged regarding the long-term effects of certain widely prescribed medications. The transition from general health education to a more focused occupational exposure concern begins with recognizing that patients who have been prescribed GLP-1 receptor agonists, such as Ozempic, may experience unexpected gastrointestinal complications. Among these, gastroparesis—a condition characterized by delayed gastric emptying—has become a subject of increasing attention. This pivot from general health discourse to a targeted legal and medical inquiry is driven by the need to understand the temporal boundaries within which affected individuals may seek recourse. In North Carolina, the statute of limitations for product liability claims related to Ozempic and gastroparesis represents a critical consideration for those who believe their exposure to the medication has resulted in harm. The shift in focus thus moves from broad health education to the specific legal timelines governing claims, without delving into mechanistic explanations or citing external evidence.

Medical Evidence Linking Ozempic to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Clinical data and postmarketing reports have raised concerns about a potential link between Ozempic and gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction. This narrative examines the medical evidence, mechanistic pathways, and risk considerations for patients in North Carolina who may have developed gastroparesis after using Ozempic. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these symptoms are common, persistent or severe cases may indicate gastroparesis.

Pharmacology and Adverse Effects of Ozempic

Ozempic works by activating GLP-1 receptors, which slow gastric emptying, increase insulin secretion, and reduce appetite. This pharmacological effect is intended to improve glycemic control and promote weight loss. However, the same mechanism can lead to adverse gastrointestinal effects. In clinical trials, specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that delayed gastric emptying is a known consequence of GLP-1 receptor activation, and in some patients, this may progress to clinically significant gastroparesis.

Mechanistic Pathways and Warning Adequacy

The primary mechanism linking Ozempic to gastroparesis is its effect on gastric motility. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation inhibits gastric emptying. This effect is dose-dependent and can be pronounced in susceptible individuals. Postmarketing reports have highlighted rare cases of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This finding underscores the potential for severe delayed gastric emptying, which is a hallmark of gastroparesis. While the label does not explicitly list gastroparesis as an adverse reaction, the constellation of gastrointestinal symptoms and the risk of retained gastric contents support a plausible mechanistic link. The current prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that more patients discontinued treatment due to these reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the warning about pulmonary aspiration in surgical patients is included in the warnings and precautions section (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This may be insufficient to alert patients and healthcare providers to the risk of chronic gastroparesis. For affected patients, the adequacy of warnings is a critical factor in legal claims, as it relates to whether the manufacturer provided sufficient information to allow informed decision-making.

Legal Considerations and Statute of Limitations in North Carolina

Patients in North Carolina who develop gastroparesis after using Ozempic may have legal recourse if they can demonstrate that the drug caused their condition and that the manufacturer failed to provide adequate warnings. The statute of limitations for product liability claims in North Carolina is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Given that gastroparesis symptoms may develop gradually, the timeline between exposure and documented harm is important. Patients should seek medical documentation of their diagnosis and the temporal relationship to Ozempic use. Consulting with an attorney experienced in pharmaceutical litigation is advisable to evaluate the specific facts of the case. The onset of gastroparesis symptoms after starting Ozempic can vary. In clinical trials, gastrointestinal adverse reactions were most common during dose escalation, suggesting that early exposure may trigger symptoms. However, chronic use may lead to persistent gastric emptying delay. Patients who experience severe or prolonged nausea, vomiting, or abdominal pain should undergo diagnostic testing for gastroparesis. Documenting the timeline—when Ozempic was started, when symptoms began, and when a formal diagnosis was made—is essential for both medical management and legal purposes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For gastroparesis linked to Ozempic, this means patients must file a claim within three years of recognizing their condition and its potential connection to the medication.

Does Ozempic cause gastroparesis?

Clinical data and postmarketing reports indicate that Ozempic can cause significant gastrointestinal adverse reactions, including delayed gastric emptying that may manifest as gastroparesis. While the drug's label acknowledges gastrointestinal side effects, it does not specifically warn about gastroparesis, which may be inadequate for patients who develop this condition.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.